|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.92 USD | -2.76% |
|
-3.03% | -1.57% |
| Jan. 17 | Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks | MT |
| Jan. 17 | Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks | MT |
| Capitalization | 248B 238B 225B 201B 355B 21,354B 396B 2,732B 1,012B 8,810B 929B 910B 38,560B | P/E ratio 2024 * |
13.9x | P/E ratio 2025 * | 11.1x |
|---|---|---|---|---|---|
| Enterprise value | 270B 260B 246B 220B 387B 23,317B 432B 2,983B 1,105B 9,620B 1,014B 993B 42,103B | EV / Sales 2024 * |
4.23x | EV / Sales 2025 * | 3.82x |
| Free-Float |
70.72% | Yield 2024 * |
3.11% | Yield 2025 * | 3.27% |
More valuation ratios
* Estimated data
More news
Last Transcript: Merck & Co., Inc.
More recommendations
More press releases
More news
| 1 day | -2.76% | ||
| 1 week | -3.03% | ||
| Current month | -1.57% | ||
| 1 month | -0.13% | ||
| 3 months | -9.92% | ||
| 6 months | -22.14% | ||
| Current year | -1.57% |
1 week
97.92
100.90
1 month
97.92102.97
Current year
97.92102.97
1 year
94.48134.63
3 years
72.88134.63
5 years
65.25134.63
10 years
45.69134.63
| Director | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 58 | 2021-06-30 |
| Director of Finance/CFO | 56 | 2021-03-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 56 | 2020-07-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 64 | 2007-11-26 |
Patricia Russo
BRD | Director/Board Member | 72 | 1995-08-31 |
Robert Davis
CHM | Chairman | 58 | 2022-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.34% | 335 M€ | -2.98% | - | |
| 5.61% | 30 M€ | +1.14% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -2.76% | -3.03% | -17.64% | +21.26% | 248B | ||
| -4.21% | -9.00% | +15.45% | +198.49% | 653B | ||
| -0.50% | +1.77% | -9.06% | -11.03% | 354B | ||
| -4.22% | -10.08% | -24.73% | +73.23% | 341B | ||
| -1.23% | -2.93% | +4.12% | +28.96% | 303B | ||
| +0.57% | +0.76% | +9.34% | -26.90% | 236B | ||
| -1.32% | -0.26% | +2.72% | +22.08% | 206B | ||
| -0.10% | -1.72% | -4.87% | +9.63% | 197B | ||
| -0.72% | -1.87% | -7.00% | -51.34% | 149B | ||
| +0.99% | +0.71% | -11.60% | +18.88% | 146B | ||
| Average | -1.35% | -1.83% | -4.33% | +28.33% | 283.38B | |
| Weighted average by Cap. | -1.96% | -3.21% | -1.98% | +56.47% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 64.01B 61.55B 58.11B 52.04B 91.65B 5,518B 102B 706B 262B 2,276B 240B 235B 9,964B | 67.44B 64.85B 61.22B 54.83B 96.56B 5,814B 108B 744B 276B 2,398B 253B 248B 10,498B |
| Net income | 17.61B 16.94B 15.99B 14.32B 25.22B 1,518B 28.12B 194B 71.99B 626B 66.05B 64.69B 2,742B | 21.95B 21.11B 19.93B 17.85B 31.44B 1,893B 35.06B 242B 89.74B 781B 82.34B 80.64B 3,418B |
| Net Debt | 22.76B 21.89B 20.66B 18.51B 32.59B 1,962B 36.35B 251B 93.04B 810B 85.37B 83.61B 3,543B | 10B 9.62B 9.08B 8.13B 14.32B 862B 15.97B 110B 40.87B 356B 37.5B 36.73B 1,557B |
More financial data
* Estimated data
Employees
71,000
Sector
Pharmaceuticals
Calendar
2025-02-04
- Q4 2024 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-01-17 | 97.92 $ | -2.76% | 16,181,960 |
| 25-01-16 | 100.70 $ | +0.61% | 7,749,642 |
| 25-01-15 | 100.09 $ | +0.44% | 9,170,335 |
| 25-01-14 | 99.65 $ | -1.32% | 10,927,440 |
Delayed Quote Nyse, January 17, 2025 at 04:00 pm EST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
97.92USD
Average target price
125.55USD
Spread / Average Target
+28.22%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRK Stock
